Surveying native speakers to find the proportions of registers used in Levantine Arabic
Register Studies · 17.08.2026 · 8 (1) · 70-93
DOI: 10.1075/rs.25002.fli ↗Kurz gefasst
Fachartikel in der Zeitschrift Register Studies, online erschienen am 11.06.2026. Verfasst von Andrea Flinn. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fulbright Association.
Abstract (Originalsprache)
Corpora consisting of Levantine Arabic, the dialects spoken in Jordan, Lebanon, Palestine, and Syria, include a narrow range of registers and are rarely based on a careful domain description, limiting their ability to represent the target domain. The purpose of this study is to describe the proportions of registers used within Levantine Arabic by conducting a Parameters of Language Use Survey ( Hashimoto 2024 ), so that subsequent corpora can better represent the Levantine dialects. The registers used (e.g., conversations, song lyrics, audio/video sharing) and their frequency were identified. As expected for a traditionally oral variety of Arabic, much language use consisted of conversation (61.1%). Another 16.4% consisted of digital language use, most of which was written, reflecting a noteworthy change precipitated by the advent of Web 2.0. Results can be used to compare varieties of Arabic including MSA, and inform research and corpus design.
Förderung
- Fulbright Association
Zitieren
APA
Flinn, A. (2026). Surveying native speakers to find the proportions of registers used in Levantine Arabic. Register Studies, 8(1), 70-93. https://doi.org/10.1075/rs.25002.fli
Vancouver
Flinn A. Surveying native speakers to find the proportions of registers used in Levantine Arabic. Register Studies. 2026;8(1):70-93. doi:10.1075/rs.25002.fli
BibTeX
@article{Flinn2026,
author = {Flinn, Andrea},
title = {Surveying native speakers to find the proportions of registers used in Levantine Arabic},
journal = {Register Studies},
year = {2026},
volume = {8},
number = {1},
pages = {70--93},
doi = {10.1075/rs.25002.fli}
}
EUVIMED